Supporters

Alexion Pharma
www.alexionpharma.eu
Alexion is a global biopharmaceutical company focused on serving patients with severe and rare disorders through innovation, development and commercialisation of life-transforming therapeutic products. Alexion developed and markets Soliris® (eculizumab), a treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). Alexion is developing other highly innovative product candidates, which are being investigated across multiple severe and rare disorders, including hypophosphatasia (HPP), an ultra-rare, genetic, life-threatening metabolic disease. For more information please see www.alexionpharma.eu or HPPsource.eu.

American Society for Bone and Mineral Research (ASBMR)
www.asbmr.org
The American Society for Bone and Mineral Research (ASBMR) is the leading professional, scientific and medical society established to bring together clinical and experimental scientists involved in the study of bone and mineral metabolism. ASBMR encourages and promotes the study of this expanding field through annual scientific meetings, an official journal (Journal of Bone and Mineral Research), the Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, advocacy and interaction with government agencies and related societies. ASBMR is pleased to provide travel support for young investigators to attend scientific meetings worldwide, including to the 7th ICCBH Meeting.

Amgen (Europe) GmbH
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

Biomedica
www.bmgrp.com
Biomedica Immunoassays provides internationally recognized, high quality ELISAs in the field of cardiovascular and renal diseases as well as bone and mineral disorders. Biomedica's ELISAs are fully validated for clinical research using serum-based calibrators and controls thus allowing researchers to collect biologically reliable data.

Biomedica’s customers include numerous top ranking scientific institutions worldwide, well-known CROs, and laboratories in the pharmaceutical industry. Biomedica has become a world-wide market leader with a continuously growing portfolio which includes ELISAs for FGF23, Sclerostin, Osteoprotegerin, and FREE soluble RANKL. The majority of Biomedica’s assays are CE marked and ready for use in IVD.

Clementia
www.clementiapharma.com
Clementia is a privately held, clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people living with rare disease. Clementia is advancing a novel retinoic acid receptor gamma agonist, palovarotene, to address diseases of heterotopic ossification. Fibrodysplasia ossificans progressiva (FOP) is a severely disabling genetic disease characterized by soft tissue swellings and heterotopic ossification in muscle and other connective tissues. A Phase 2 clinical trial is currently evaluating the long-term safety and efficacy of palovarotene treatment in individuals with FOP. For more information about Clementia, visit www.clementiapharma.com. For more information about the Phase 2 clinical trial, visit www.clinicaltrials.gov.

Austrian Society for Bone and Mineral Research (AusSBMR/ÖGKM)
www.oegkm.at
The society was funded 25 years ago and our aim is the endorsement and support of research, teaching and clinical routine in the field of bone and mineral research, the encouragement of cooperations between different professions and specialties in science and practice and ultimately the international representation of Austrian scientists working in this field.
Supporters

DSM
www.dsm.com
Royal DSM is a global science-based company active in health, nutrition and materials. By connecting its unique competences in Life Sciences and Materials Sciences DSM is driving economic prosperity, environmental progress and social advances to create sustainable value for all stakeholders simultaneously. DSM delivers innovative solutions that nourish, protect and improve performance in global markets such as food and dietary supplements, personal care, feed, medical devices, automotive, paints, electrical and electronics, life protection, alternative energy and bio-based materials. DSM and its associated companies deliver annual net sales of about €10 billion with approximately 25,000 employees. The company is listed on Euronext Amsterdam. More information can be found on our website.

European Calcified Tissue Society
www.ectsoc.org
The European Calcified Tissue Society (ECTS) is the major organisation in Europe for researchers and clinicians working in calcified tissues and related fields. For over 50 years the society has been a forum for wide-ranging high quality research through its annual congress and training courses.

ECTS Congress 2016
Rome, Italy, 14-17 May 2016

ECTS PhD training courses:
13-16 September 2015, Tuscany, Italy;
2-5 July 2016, Oxford, UK

IDS
www.idsplc.com
Immunodiagnostic Systems Holdings PLC (Hereafter referred to as IDS) is a leading in-vitro diagnostic solution provider to the clinical laboratory market. We develop, manufacture, and market innovative immunoassays and automated immunoanalyser technologies to provide improved diagnostic outcomes for patients. Our immunoassay portfolio is a combination of an endocrinology specialty testing menu and assay panels in complementary fields. IDS will be exhibiting the IDS-iSYS Multi-Discipline Automated System (hereafter referred to as the IDS-iSYS), specifically designed with the flexibility to accommodate unique and challenging assay requirements. The automated system brings testing efficiency and uncompromised quality to specialty immunoassay testing in laboratories of all types and volumes. Please visit us to find out more about the IDS-iSYS and our fully automated 1,25-Dihydroxy Vitamin D assay complete with on-board sample purification. We would love the opportunity to discuss our complete range of automated bone markers including the new automated TRAcP 5b assay for the quantitative determination of Tartrate specific Acid Phosphatase 5b (TRAcP) in human serum and heparin plasma.

International Bone and Mineral Society
www.ibmsonline.org
The International Bone and Mineral Society is the organization that facilitates the generation and dissemination of knowledge of bone and mineral metabolism through communication, community, training and multidisciplinary meetings throughout the world. IBMS is a global network of over 2,500 researchers, clinicians, and companies all dedicated to the promotion of bone health through global collaboration. IBMS is proud of its two publications, BoneKEy® Reports and IBMSBoneKEy®. IBMS BoneKEy® provides the bone field with an open access, online knowledge environment for scientific exchange and community growth based on expert scientific content. The official scientific journal of IBMS, BoneKEy Reports, is recognized as one of the leading journals in the bone field. BoneKEy Reports publishes reviews, original research articles, commentaries and laboratory methods.

International Osteoporosis Society
www.iofbonehealth.org
The International Osteoporosis Foundation (IOF) is the world’s largest nongovernmental organization dedicated to the prevention, diagnosis and treatment of osteoporosis and related musculoskeletal diseases. IOF members include committees of scientific researchers, leading companies, as well as more than 230 patient, medical and research societies. IOF’s mission is to make the maintenance of bone, muscle and joint health a worldwide priority. Its primary goals are to: motivate people to take action for prevention and treatment; foster the education and training of healthcare professionals; lobby for policy change so that the prevention, diagnosis and treatment of musculoskeletal disorders becomes standard worldwide; promote medical innovation and improve patient care; and work with institutions or societies having similar objectives.
Internis Pharmaceuticals Ltd
www.internisvitd3.com
Founded in 2010, Internis is a UK speciality pharmaceutical company engaged in the development and commercialisation of highly effective and innovative new medicines aimed at the treatment and prevention of a range of common bone disorders, such as osteoporosis and vitamin D3 deficiency.

Kellogg’s
www.kelloggsnutrition.com
Kellogg’s have had nutrition at the heart of what we do for more than 100 years ago, since W.K. Kellogg recognised the possibilities in a single grain. We continue to be driven by our founder, W.K Kellogg’s, principle to make quality products for a healthier world. We know that eating breakfast is important, but what you choose to eat for the first meal of the day also matters. Fibre, wholegrain, vitamins and minerals are important for good health. These can be found in breakfast cereal and we know that those who choose to eat breakfast cereals have improved intakes of many nutrients, compared to those who don't. We are committed to helping as many people as possible get a great start to help set them up for the day’s activities, whether at work, home or school.

Novo Nordisk
www.novonordisk.com
Novo Nordisk is a global healthcare company with 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy.

Novo Nordisk employs approximately 41,500 employees in 75 countries, and markets its products in more than 180 countries.

Growth hormone is important in helping children grow. It is also plays a role in the overall health of children and adults.

With over 25 years’ experience, Novo Nordisk is committed to the growth hormone category.

Pfizer
www.pfizer.com
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products.

Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.

Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. To learn more, please visit our website.

Sandoz
www.sandoz.com

Stratec Medizintechnik GmbH
www.galileo-training.com
Stratec Medizintechnik is the world’s most successful producer of pQCT-based bone densitometry scanners for clinical and preclinical applications. Unlike in 2-dimensional absorptiometric machines pQCT derived density measures are independent of bone size. Therefore pQCT can be applied to all age groups and body sizes. Additionally geometrical properties of bone and muscle parameters can be analysed which allows a detailed diagnosis and the differentiation of disuse osteopenia from true osteoporosis.

Novotec Medical is manufacturer of Galileo vibration training devices for muscle stimulation and of Leonardo motion analysis systems (mechanography). Due to the side alternating technology a natural movement similar to human gait is employed. Several studies showed the benefits in the improvement of mobility of chronically ill children.

UCB
www.ucb.com
UCB is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 8500 people in approximately 40 countries, the company generated revenue of € 3.4 billion in 2013. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news
Ultragenyx
www.ultragenyx.com

Ultragenyx is a clinical-stage biopharmaceutical company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. Ultragenyx formed a collaboration with Kyowa Hakko Kirin Co., Ltd. (KHK) to jointly develop and commercialize KRN23 for the treatment of XLH. KRN23 is a fully human monoclonal antibody administered via subcutaneous injection that is designed to bind and reduce the biological activity of FGF23 in patients with XLH.

Ultragenyx has two ongoing clinical trials with KRN23 in XLH: a Phase 2 clinical study in children ages 5 to 12 and an adult Phase 2b extension study in adults. Additional studies in children and adults are being planned for later in the year. Ultragenyx is also sponsoring a Phase 2 study of KRN23 in a small number of tumor-induced osteomalacia (TIO) patients.